Elutia to Sell Simpliderm for up to $11M

Dow Jones

Jul 17

Elutia said it signed a definitive agreement to sell its SimpliDerm business to Cellution Biologics for up to $11 million.

The deal includes $8 million at closing and up to $3 million in technology transfer and commercial milestone payments over 18 months. Closing is expected in the second half of 2026.

The company said the proceeds provide non-dilutive capital and sharpen its focus on NXT-41x, a next generation antibiotic-eluting biomatrix for plastic and reconstructive surgery.

Elutia plans a targeted commercial launch of NXT-41x in 2027 and is developing it for a U.S. market the company sizes at about $1.5 billion.

Write to Doc Louallen at Doc.Louallen@wsj.com

(END) Dow Jones Newswires

July 16, 2026 16:46 ET (20:46 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2652227244"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2652227244\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2652227244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 04:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652227244","market":"sh","top_or_hot":-1,"title":"Elutia to Sell Simpliderm for up to $11M","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ELUT\">Elutia</a> said it signed a definitive agreement to sell its SimpliDerm business to Cellution Biologics for up to $11 million. \n</p>\n<p>\n  The deal includes $8 million at closing and up to $3 million in technology transfer and commercial milestone payments over 18 months. Closing is expected in the second half of 2026. \n</p>\n<p>\n  The company said the proceeds provide non-dilutive capital and sharpen its focus on NXT-41x, a next generation antibiotic-eluting biomatrix for plastic and reconstructive surgery. \n</p>\n<p>\n  Elutia plans a targeted commercial launch of NXT-41x in 2027 and is developing it for a U.S. market the company sizes at about $1.5 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 16, 2026 16:46 ET (20:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elutia to Sell Simpliderm for up to $11M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElutia to Sell Simpliderm for up to $11M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-17 04:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ELUT\">Elutia</a> said it signed a definitive agreement to sell its SimpliDerm business to Cellution Biologics for up to $11 million. \n</p>\n<p>\n  The deal includes $8 million at closing and up to $3 million in technology transfer and commercial milestone payments over 18 months. Closing is expected in the second half of 2026. \n</p>\n<p>\n  The company said the proceeds provide non-dilutive capital and sharpen its focus on NXT-41x, a next generation antibiotic-eluting biomatrix for plastic and reconstructive surgery. \n</p>\n<p>\n  Elutia plans a targeted commercial launch of NXT-41x in 2027 and is developing it for a U.S. market the company sizes at about $1.5 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 16, 2026 16:46 ET (20:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2652227244","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652227244","pubTimestamp":1784234760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Elutia said it signed a definitive agreement to sell its SimpliDerm business to Cellution Biologics for up to $11 million.The deal includes $8 million at closing and up to $3 million in technology transfer and commercial milestone payments over 18 months. Closing is expected in the second half of 2026.The company said the proceeds provide non-dilutive capital and sharpen its focus on NXT-41x, a next generation antibiotic-eluting biomatrix for plastic and reconstructive surgery.Elutia plans a targeted commercial launch of NXT-41x in 2027 and is developing it for a U.S. market the company sizes at about $1.5 billion.Write to Doc Louallen at Doc.Louallen@wsj.com Dow Jones NewswiresJuly 16, 2026 16:46 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ELUT":"Elutia"},"translate_title":"Elutia 将以高达 1100 万美元的价格出售 Simpliderm","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELUT":1.5},"content_text":"Elutia said it signed a definitive agreement to sell its SimpliDerm business to Cellution Biologics for up to $11 million. \n\n\n  The deal includes $8 million at closing and up to $3 million in technology transfer and commercial milestone payments over 18 months. Closing is expected in the second half of 2026. \n\n\n  The company said the proceeds provide non-dilutive capital and sharpen its focus on NXT-41x, a next generation antibiotic-eluting biomatrix for plastic and reconstructive surgery. \n\n\n  Elutia plans a targeted commercial launch of NXT-41x in 2027 and is developing it for a U.S. market the company sizes at about $1.5 billion. \n\n\n \n\n\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 16, 2026 16:46 ET (20:46 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}